학술논문
TARGET: A Phase II, Open-Label, Single-Arm Study of 5-Year Adjuvant Osimertinib in Completely Resected EGFR-Mutated Stage II to IIIB NSCLC Post Complete Surgical Resection
Document Type
Article
Author
Source
In: Clinical Lung Cancer . (Clinical Lung Cancer, January 2024, 25(1):80-84)
Subject
Language
English
ISSN
19380690
15257304
15257304